3 completed, 1 recruiting, 1 unknown. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Antigens: new trials by email Literature Review of Antigens trials Research Report on Antigens
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older Low dose antigen and low dose adjuvant of LYB004, Low dose antigen and high dose adjuvant of LYB004, High dose antigen and low dose adjuvant of LYB004 - Herpes Zoster (HZ) | Phase 1 | Recruiting | Guangzhou Patronus Biotech Co., Ltd. | 92 | 2025-03-13 | 2025-04-01 |
| Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer Autologous dendritic cells pulsed with antigen - NSCLC | Phase 1 / Phase 2 | Unknown | Henan Cancer Hospital | 30 | 2019-12-01 | 2019-12-16 |
| Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above Adjuvanted, trivalent subunit influenza vaccine, Adjuvant level modified adjuvanted, trivalent subunit influenza vaccine, Antigen level modified adjuvanted, trivalent subunit influenza vaccine - Influenza | Phase 1 | Completed | Seqirus | 196 | 2014-06-01 | 2016-07-29 |
| A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) Antigen (Ag85B-ESAT-6), Antigen (Ag85B-ESAT-6) with adjuvant (IC31) - Tuberculosis | Phase 1 | Completed | Statens Serum Institut | 39 | 2008-12-01 | 2015-04-17 |
| Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation - Influenza | Phase 1 / Phase 2 | Completed | Alachua Government Services, Inc. | 110 | 2007-07-01 | 2015-10-09 |
Influenza, Human (2) · Chickenpox (1) · Herpes Zoster (1) · Tuberculosis (1)
Alachua Government Services, Inc. (1) · Guangzhou Patronus Biotech Co., Ltd. (1) · Henan Cancer Hospital (1) · Seqirus (1) · Statens Serum Institut (1)
China (2) · Germany (1) · Hong Kong (1) · Singapore (1)
Jemal Hussein, MD (1) · Peter Bang, Msc (1) · Renfeng Fan (1) · Zibing Wang (1)